Navigation Links
CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million
Date:5/22/2008

BRANFORD, Conn., May 22 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today the completion of a series of privately negotiated transactions in which the Company sold the 5,000,000 shares of TopoTarget common stock issued to the Company as partial payment for the sale of CuraGen's ownership in belinostat. After expenses, CuraGen will receive approximately $12 million in cash.

"We are pleased to announce the planned, orderly liquidation of our position in TopoTarget stock. These sales, when added to the up-front cash payment we received from TopoTarget on April 22, 2008, bring the total cash realized by CuraGen to approximately $38 million," stated Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "We also retain further potential upside related to belinostat consisting of up to $6 million in potential milestone payments on future net sales and sublicenses of belinostat."

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a clinical-stage biopharmaceutical company developing promising approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's potential economic benefits from future net sales and sublicense of belinostat may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the period ended March 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CuraGen Contacts:

Sean Cassidy

Vice President and Chief Financial Officer

scassidy@curagen.com

Glenn Schulman, Pharm.D.

Director Medical Communications

gschulman@curagen.com

(888) 436-6642

CRGN-F


'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CuraGen Reports First Quarter 2008 Financial Results
2. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
3. CuraGen Reports Third Quarter 2007 Financial Results
4. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Actifirm Sells Out in First Hour Appearance on QVC
6. Blackstone Sells Gerresheimer Stake
7. Isolagen, Inc. Sells Switzerland Facility
8. On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group
9. Medifast Franchise Systems Sells First Territory in Baltimore
10. HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million
11. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... LARKR™ , an innovative new smartphone app ... across the country to join its online treatment platform. , Launching in just ... a substantially greater number of people in need nationwide, and to supplement their traditional ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing teeth ... with or without a referral. Dr. Cotey is a trusted dentist who has placed ... replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged to find ...
(Date:6/25/2017)... , ... June 25, 2017 , ... Republicans in the ... and replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the ... will need to be reconciled in committee, or the House will have to take ...
(Date:6/25/2017)... ... ... heatwave currently bearing down on Northern California pushing temperatures to the maximum, many people are ... with laser hair removal. , The process of summer waxing and constantly shaving unwanted ... want to do is get out, dive in and cool off. There is a way ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... PA at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... experience, exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... CAESAREA, Israel , May 30, 2017 DarioHealth Corp. ... and big data solutions, today announced that it will be presenting ... 2017, at 8:00 AM PT. Erez Raphael , CEO, of ... The conference will be held on June 6th & 7th, ... 180 companies in the small / micro-cap space. ...
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology: